2018
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, Weinheimer S, Marsolais C, Lewis S. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. New England Journal Of Medicine 2018, 379: 645-654. PMID: 30110589, DOI: 10.1056/nejmoa1711460.Peer-Reviewed Original ResearchConceptsPhase 3 studyHIV-1 infectionViral loadBackground regimenVirologic failureAdverse eventsWeek 25Multidrug-resistant HIV-1 infectionMDR HIV-1 infectionMean baseline viral loadMultidrug-resistant HIV-1Human immunodeficiency virus type 1Immunodeficiency virus type 1Control periodMultiple antiretroviral therapiesViral load decreaseCommon adverse eventsMean CD4 countPrimary end pointSerious adverse eventsBaseline viral loadProportion of patientsHIV-1 RNALimited treatment optionsVirus type 1
2016
Epigenome-wide differential DNA methylation between HIV-infected and uninfected individuals
Zhang X, Justice AC, Hu Y, Wang Z, Zhao H, Wang G, Johnson EO, Emu B, Sutton RE, Krystal JH, Xu K. Epigenome-wide differential DNA methylation between HIV-infected and uninfected individuals. Epigenetics 2016, 11: 750-760. PMID: 27672717, PMCID: PMC5094631, DOI: 10.1080/15592294.2016.1221569.Peer-Reviewed Original ResearchDifferential DNA methylationDNA methylationLarge-scale epigenome-wide association studyMajor histocompatibility complex (MHC) class I gene expressionNovel host genesEpigenome-wide association studiesClass I gene expressionVeterans Aging Cohort StudyEpigenome-wide significant CpGsEpigenetic controlHIV-1 infectionHost genesI gene expressionEpigenetic changesHost genomeCARD domainKey regulatorGene expressionAssociation studiesSignificant CpGsGene 5CpG sitesMethylationCell typesLower methylation